Investor Relations

Investor Relations

Cyxone is a Swedish biotech company that develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders in convenient administration forms.

With three unique projects, all developing towards important and potentially value-creating milestones, Cyxone is well positioned to deliver consequential benefits for patients, the health care system as well as for its shareholders. Cyxone’s goal is to out-license projects to strong partners after Phase 2 clinical trials to maximize their potential.

Cyxone’s financial statements are prepared in accordance with International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB) as adopted by the EU.

Download Cyxone’s Significant Accounting Principles as PDF

Investor Relations contact
Tara Heitner, CEO

Latest Press Release

Financial Calendar

Silent period Q1, 2020

Start date: 13 April 2021

End date: 12 May 2021

The interim report for Q1 2021 will be published on 12 May and the silent period starts 13 April 2021.

Interim Report Q1 2021

Date: 12 May 2021

Annual General Meeting

Date: 3 June 2021